Dr. Hoffman-Censits is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Education & Training
- Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2002 - 2006
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2002
- Trinity CollegeB.S., Neuroscience, 1995
Certifications & Licensure
- DC State Medical License 2018 - 2027
- MD State Medical License 2018 - 2026
- PA State Medical License 2005 - 2026
- VA State Medical License 2024 - 2026
- DE State Medical License 2017 - 2019
- NJ State Medical License 2017 - 2019
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
- Senior Achievement Award National Alumni Association, 1995
- Join now to see all
Clinical Trials
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
- A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
- Tesetaxel for Previously Treated Patients With Bladder Cancer Start of enrollment: 2010 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsNectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study.Ezra G Baraban, Evangelia Vlachou, Sunil Patel, Max Kates, Burles Johnson
The Prostate. 2025-04-01 - Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).Daniel M Geynisman, Philip H Abbosh, Eric Ross, Matthew R Zibelman, Pooja Ghatalia
Journal of Clinical Oncology. 2025-03-20 - Clinical and histopathological characterization of enfortumab vedotin-associated cutaneous toxicities: A case series.Ista A Egbeto, Evangelia Vlachou, Daniela Barata Herrera, Stephanie Russell, Joel C Sunshine
JAAD Case Reports. 2025-03-01
Journal Articles
- Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen TherapiesDan TD, Eldredge-Hindy HB, Hoffman-Censits, J, Lin J, Kelly WK, Gomella LG, Lallas CD, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB, Am J Clin Oncol, 1/25/2015
- An Open Label Randomized Phase II Study Of Pasireotide With And Without Everolimus In Castrate-Resistant Chemotherapy-Naïve Prostate Cancer PatientsJ. Lin, J. Hoffman-Censits, Journal of Cancer Treatment Communications, 1/1/2015
- Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based chemotherapy in Muscle-invasive Bladder CancerPlimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, V..., Eur Urol, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a multicenter Phase II study (IMvigor 210).Jonathan E. Rosenberg, Daniel P. Petrylak, Oyewale Abidoye, Michiel van Der Heijden, Jean Hoffman-Censits, Andrea Necchi, Peter O'Donnell, Ani Balmanoukian, Yohann Lor..., European Cancer Congress, 1/1/2015
- The First Report of RTOG 0622: A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer...R. Valicenti, S. Pugh, E. Trabulsi, O. Sartor, M. Girvigian, S. Rosenthal, S. Williams, J. Hoffman-Censits, J. Schallenkamp, H. Sandler, ASTRO, 1/1/2015
- Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.Plimack ER, Dunbrack R, Brennan T, Andrake M, Zhou Y, Serebriiskii I, Dulaimi E, Hoffman-Censits J, Bilusic M, Wong Y, Kutikov A, Viterbo R, Greenberg RE, Chen D, Lall..., ASCO GU Meeting Abstracts, 1/1/2015
- Join now to see all
Lectures
- Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Update on Clinical Trials in Urothelial CarcinomasKing of Prussia, PA - 1/1/2015
- Testis Cancer Treatment with focus on stage I disease1/1/2015
- Join now to see all
Press Mentions
- Jean Hoffman-Censits, MD, on Rare, Nonurothelial Subtypes of Bladder CancerDecember 26th, 2024
- Improved Patient Selection Needed to Optimize Expanding Options in Bladder CancerOctober 27th, 2017
- Atezolizumab Update Affirms Activity in Bladder CancerJanuary 9th, 2016
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: